tate the application's broad, long-term objectives and specific aims, making reference to the health relatedness ofthe project (i.e., relevance to the mission of the agency). Describe concisely the research design and methods for achieving these goals. Describethe rationale and techniques you will use to pursue these goals.In addition, in two or three sentences, describe in plain, lay language the relevance of this research to public health. If the application is funded, thisdescription, as is, will become public information. Therefore, do not include proprietary/confidential information. Enhanced heat shock protein (HSP) expression protects cells and tissues from injury. Further, enhanced HSP expression improves survival in experimental models of critical illness. However, these findings have not been applied in a clinical setting, as laboratory inducers of HSPs are not safe for human administration. Thus, this powerful tool, that may significantly improve clinical outcome, has yet to be utilized. Our laboratory has shown glutamine (GLN) can safely enhance HSP expression in tissues of critically ill and injured animals and established HSP induction is necessary for GLN's beneficial effect following experimental illness. In a trial of critically ill patients we demonstrated GLN enhanced HSP-70 levels, which correlated with improved outcome. However, the mechanism by which GLN induces HSP expression is unknown. We hypothesize GLN induces HSP expression via activation of the O-linked glycosylation pathway (O-GlcNAc), which is known to depend on GLN as a rate limiting substrate. This pathway can activate key transcription factors required for HSP induction. Our preliminary data indicates GLN increases the activity of the O-GlcNAc pathway and nuclear translocation and activation of key inducers of the HSP pathway, such as Sp1 and heat shock factor-1 (HSF-1). Further, siRNA inhibition of one of the key O-GlcNAc pathway enzymes significantly blunts the GLN-mediated increase in HSP expression. The major focus of this proposal is to determine the mechanism by which GLN induces HSP expression. Our hypothesis is GLN acts via transport into the cell and metabolism by the O-GlcNAc pathway to increase O-linked glycosylation of key transcription factors required for HSP gene activation, which then increases the expression of HSPs. To address this hypothesis, we propose three specific aims: This project will utilize cellular and animal models of illness/injury and employ chemical/genetic inhibition of key enzymes in these pathways to address the following specific aims: 1) Evaluate the role of GLN transport and metabolism via the O-GlcNAc pathway in stress/injury. 2) Evaluate via promoter truncation which promoter regions are key for GLN-mediated HSP expression. Then, determine the effect of GLN on nuclear translocation and transactivation of key transcription factors responsible for HSP expression. 3) Evaluate effects of GLN transport, metabolism, and transcriptional activation on the following cellular and in vivo endpoints: a) HSP expression (multiple families of HSPs), b) tissue/cellular injury, and c) cell volume. This project will elucidate how GLN induces HSP expression in clinical illness and injury. We believe GLN will be able to be administered as a pharmacologic agent prior to surgery or at onset of critical illness/tissue injury (with admittance to ICU/emergency room) to enhance HSP expression and improve survival. This project will elucidate how glutamine induces protective heat shock protein expression in clinical illness and injury. We believe glutamine will be able to be administered as a pharmacologic agent prior to surgery or at onset of critical illness/tissue injury (with admittance to ICU/emergency room) to enhance heat shock protein expression and improve survival.

National Institute of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
Research Project (R01)
Project #
Application #
Study Section
Surgery, Anesthesiology and Trauma Study Section (SAT)
Program Officer
Somers, Scott D
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Colorado Denver
Schools of Medicine
United States
Zip Code
Khailova, Ludmila; Petrie, Benjamin; Baird, Christine H et al. (2014) Lactobacillus rhamnosus GG and Bifidobacterium longum attenuate lung injury and inflammatory response in experimental sepsis. PLoS One 9:e97861
Baird, Christine H; Niederlechner, Stefanie; Beck, Ryan et al. (2013) L-Threonine induces heat shock protein expression and decreases apoptosis in heat-stressed intestinal epithelial cells. Nutrition 29:1404-11
Khailova, Ludmila; Baird, Christine H; Rush, Aubri A et al. (2013) Lactobacillus rhamnosus GG improves outcome in experimental pseudomonas aeruginosa pneumonia: potential role of regulatory T cells. Shock 40:496-503
Weitzel, Lindsay B; Ambardekar, Amrut V; Brieke, Andreas et al. (2013) Left ventricular assist device effects on metabolic substrates in the failing heart. PLoS One 8:e60292
Khailova, Ludmila; Frank, Daniel N; Dominguez, Jessica A et al. (2013) Probiotic administration reduces mortality and improves intestinal epithelial homeostasis in experimental sepsis. Anesthesiology 119:166-77
Niederlechner, Stefanie; Baird, Christine; Petrie, Benjamin et al. (2013) Epidermal growth factor receptor expression and signaling are essential in glutamine's cytoprotective mechanism in heat-stressed intestinal epithelial-6 cells. Am J Physiol Gastrointest Liver Physiol 304:G543-52
Wischmeyer, Paul (2011) Nutritional pharmacology in surgery and critical care: 'you must unlearn what you have learned'. Curr Opin Anaesthesiol 24:381-8
Xue, Hongyu; Sufit, Alexandra J D; Wischmeyer, Paul E (2011) Glutamine therapy improves outcome of in vitro and in vivo experimental colitis models. JPEN J Parenter Enteral Nutr 35:188-97
Weitzel, Lindsay-Rae B; Wischmeyer, Paul E (2010) Glutamine in critical illness: the time has come, the time is now. Crit Care Clin 26:515-25, ix-x
Wischmeyer, Paul E; Heyland, Daren K (2010) The future of critical care nutrition therapy. Crit Care Clin 26:433-41, vii

Showing the most recent 10 out of 13 publications